High MICAL-L2 promotes cancer progression and drug resistance of renal clear cell carcinoma cell via stabilization of ACTN4 and following vimentin expression
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Kidney clear cell carcinoma (KIRC) continues to be a substantial contributor to cancer-associated fatalities nowadays. Targeted therapies persist as the conventional method of KIRC treatment. Nevertheless, the development of resistance to those drug emerges as a significant impediment to renal cancer management. MICALL2, a member of the molecules that interact with the CasL family (MICALs), plays pivotal roles in cytoskeleton rearrangement. This study sought to elucidate the clinical relevance of MICAL-L2 in KIRC and its regulatory mechanism in cancer progression and resistance to therapy. The Cancer Genome Atlas data mining was utilized to assess the expression of MICAL-L2 in KIRC tissues. Statistical analysis of immunohistochemistry and the Kaplan–Meier Plotter database were employed to investigate the clinical significance of MICALL2. A series of in vitro experiments, encompassing assays for CCK-8, EDU staining, wound healing and transwell migration, flow cytometry, RT-PCR, co-immunoprecipitation analysis were conducted to demonstrate the effects of MICAL-L2 on the drug sensitivity of KIRC cells and to elucidate the underlying molecular mechanisms. MICAL-L2 is overexpressed in KIRC tissues. Elevated MICAL-L2 levels correlate with reduced survival rate and a diminished response to drug therapy in KIRC patients. MICAL-L2 overexpression stimulates cell proliferation, migration and renders KIRC cells insensitive to Sunitinib and Everolimus, two traditional therapeutics for KIRC. Furthermore, MICAL-L2 promotes progression and resistance to therapy in KIRC cells by interacting with its downstream regulator Alpha-actinin-4 (ACTN4) in a Rab13-dependent manner, then reducing ACTN4 degradation, and thereby leading to augmented vimentin expression in KIRC cells. These findings indicate that MICAL-L2 plays a critical role in the progression of KIRC and suggest that MICAL-L2 may function as a therapeutic target in KIRC patients.